skip to navigation skip to content

Biopharm expansion


Apollo Therapeutics, a life sciences company led by Cambridge Judge Business School alumnus and Fellow Dr Richard Mason, completes $145 million financing.

Scientists working in a modern laboratory.

Apollo Therapeutics, a biopharmaceutical company headed by Cambridge Judge Business School MBA alumnus and Fellow Dr Richard Mason (MBA 1999), announced that it completed a $145 million financing led by Patient Square Capital, which will take a controlling position in the business.

Additional investors include Rock Springs Capital, Reimagined Ventures and UCL Technology Fund, with the new financing supporting advancement of Apollo’s pipeline and establishment of a presence in Boston, Massachusetts.

Apollo, established in 2015 and headquartered in Cambridge, England, seeks to develop potentially transformative treatments based on breakthrough discoveries.

Dr Richard Mason, who is CEO of Apollo, is a Fellow in Health Management at the Cambridge Centre for Health Leadership & Enterprise at Cambridge Judge and teaches an elective on the biotechnology industry on the School’s MBA programme. “There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development,” he said. “We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners.”